Literature DB >> 15994388

Bronchodilator response in the lung health study over 11 yrs.

N R Anthonisen1, P G Lindgren, D P Tashkin, R E Kanner, P D Scanlon, J E Connett.   

Abstract

Long-term changes in bronchodilator response in people with mild chronic obstructive pulmonary disease were assessed in this study. Changes in forced expiratory volume in one second (FEV1) in response to isoproterenol was measured in 4,194 participants in the Lung Health Study annually for 5 yrs, and again 11 yrs after study entry. Responses were quantitated in terms of mL (absolute), as per cent of the pre-bronchodilator value (relative), and as a per cent of the predicted normal value (% predicted). At baseline, the mean pre-bronchodilator FEV1 was 75.4% predicted, and responses were small. Relative and percentage predicted responses were similar in males and females; and correlated positively with methacholine reactivity, and negatively with smoking intensity and age. Baseline bronchodilator responses did not correlate with subsequent decline in FEV1. There was a substantial increase in response over the first year of the study, largely due to smoking cessation, with larger increases in those who stopped smoking. After the first year absolute responses changed little in those who maintained smoking cessation, but increased in those who did not. Mean relative and percentage predicted responses increased in all participants throughout the study. There was substantial annual variability of absolute response, and it was poorly reproducible in individual participants. In conclusion, smoking cessation increased bronchodilator response, and response did not predict the rate of decline of forced expiratory volume in one second.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15994388     DOI: 10.1183/09031936.05.00102604

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  33 in total

1.  What is the difference between FEV1 change in percentage predicted value and change over baseline in the assessment of bronchodilator responsiveness in patients with COPD?

Authors:  Wenhua Jian; Jinping Zheng; Yi Hu; Yin Li; Yi Gao; Jiaying An
Journal:  J Thorac Dis       Date:  2013-08       Impact factor: 2.895

2.  Gender and chronic obstructive pulmonary disease: why it matters.

Authors:  Meilan K Han; Dirkje Postma; David M Mannino; Nicholas D Giardino; Sonia Buist; Jeffrey L Curtis; Fernando J Martinez
Journal:  Am J Respir Crit Care Med       Date:  2007-08-02       Impact factor: 21.405

3.  Standardisation of lung function testing: helpful guidance from the ATS/ERS Task Force.

Authors:  G Laszlo
Journal:  Thorax       Date:  2006-09       Impact factor: 9.139

Review 4.  [Stage appropriate therapy for COPD].

Authors:  H Hamm
Journal:  Internist (Berl)       Date:  2006-09       Impact factor: 0.743

5.  Characterisation of phenotypes based on severity of emphysema in chronic obstructive pulmonary disease.

Authors:  Hironi Makita; Yasuyuki Nasuhara; Katsura Nagai; Yoko Ito; Masaru Hasegawa; Tomoko Betsuyaku; Yuya Onodera; Nobuyuki Hizawa; Masaharu Nishimura
Journal:  Thorax       Date:  2007-06-15       Impact factor: 9.139

6.  A randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary disease.

Authors:  Charles K N Chan; François Maltais; Chris Sigouin; Jennifer M Haddon; Gordon T Ford
Journal:  Can Respir J       Date:  2007 Nov-Dec       Impact factor: 2.409

7.  Genome-wide study identifies two loci associated with lung function decline in mild to moderate COPD.

Authors:  Nadia N Hansel; Ingo Ruczinski; Nicholas Rafaels; Don D Sin; Denise Daley; Alla Malinina; Lili Huang; Andrew Sandford; Tanda Murray; Yoonhee Kim; Candelaria Vergara; Susan R Heckbert; Bruce M Psaty; Guo Li; W Mark Elliott; Farzian Aminuddin; Josée Dupuis; George T O'Connor; Kimberly Doheny; Alan F Scott; H Marike Boezen; Dirkje S Postma; Joanna Smolonska; Pieter Zanen; Firdaus A Mohamed Hoesein; Harry J de Koning; Ronald G Crystal; Toshiko Tanaka; Luigi Ferrucci; Edwin Silverman; Emily Wan; Jorgen Vestbo; David A Lomas; John Connett; Robert A Wise; Enid R Neptune; Rasika A Mathias; Peter D Paré; Terri H Beaty; Kathleen C Barnes
Journal:  Hum Genet       Date:  2012-09-18       Impact factor: 4.132

8.  Genetic association analysis of COPD candidate genes with bronchodilator responsiveness.

Authors:  Woo Jin Kim; Craig P Hersh; Dawn L DeMeo; John J Reilly; Edwin K Silverman
Journal:  Respir Med       Date:  2008-12-25       Impact factor: 3.415

Review 9.  [Clinical value of forced expiratory volume in 1 s (FEV1) in chronic obstructive pulmonary disease].

Authors:  Adrian Gillissen; Thomas Glaab; Roland Buhl
Journal:  Med Klin (Munich)       Date:  2009-02-26

Review 10.  Genetic predisposition to accelerated decline of lung function in COPD.

Authors:  Néstor A Molfino
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.